Compare HRZN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRZN | XOMA |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.7M | 322.7M |
| IPO Year | 2010 | N/A |
| Metric | HRZN | XOMA |
|---|---|---|
| Price | $6.69 | $29.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $7.13 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 739.7K | 371.9K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 19.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $98,899,000.00 | $47,106,000.00 |
| Revenue This Year | $3.03 | $77.29 |
| Revenue Next Year | $10.24 | $34.91 |
| P/E Ratio | ★ N/A | $36.42 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $5.71 | $18.35 |
| 52 Week High | $9.99 | $39.92 |
| Indicator | HRZN | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 57.12 |
| Support Level | $6.49 | $25.30 |
| Resistance Level | $6.38 | $28.61 |
| Average True Range (ATR) | 0.13 | 1.58 |
| MACD | 0.03 | 0.66 |
| Stochastic Oscillator | 94.68 | 83.53 |
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.